PCSK9 monoclonal antibodies for the primary and secondary prevention of cardiovascular disease

BACKGROUND: Despite the availability of effective drug therapies that reduce low‐density lipoprotein (LDL)‐cholesterol (LDL‐C), cardiovascular disease (CVD) remains an important cause of mortality and morbidity. Therefore, additional LDL‐C reduction may be warranted, especially for people who are un...

Full beskrivning

Sparad:
Bibliografiska uppgifter
I publikationen:Cochrane Database Syst Rev
Huvudupphovsmän: Schmidt, Amand F, Carter, John-Paul L, Pearce, Lucy S, Wilkins, John T, Overington, John P, Hingorani, Aroon D, Casas, JP
Materialtyp: Artigo
Språk:Inglês
Publicerad: John Wiley & Sons, Ltd 2020
Länkar:https://ncbi.nlm.nih.gov/pmc/articles/PMC8094613/
https://ncbi.nlm.nih.gov/pubmed/33078867
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1002/14651858.CD011748.pub3
Taggar: Lägg till en tagg
Inga taggar, Lägg till första taggen!

Liknande verk